Role of CD4+ regulatory T cells in multiple myeloma

Creative Commons License

Ekinci D., ÖZKAN A.

CUKUROVA MEDICAL JOURNAL, cilt.42, sa.3, ss.546-551, 2017 (ESCI) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 42 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.17826/cutf.323972
  • Dergi Adı: CUKUROVA MEDICAL JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.546-551
  • Anahtar Kelimeler: Multiple myeloma, regulatory T cells, PD-1/PDL1-PDL2, B7 FAMILY, EXPRESSION, MEMBER, B7-H1, FOXP3, TRANSPLANTATION, INTERLEUKIN-10, MECHANISMS, PD-L1
  • Akdeniz Üniversitesi Adresli: Evet

Özet

In many studies, regulatory T cell increase is seen both in patients with newly diagnosed multiple myeloma and post chemotherapy patients including autologous stem cell transplants. Multiple myeloma is a malignant plasma cell disease. Regulatory T cells have a role in immune homeostasis from cancer and inflamatory conditions to autoimmune diseases. PD-1 pathway stimulates T cell population towards regulatory T cell development. It has been shown that PDL1 plays an important role in differentiating inducable regulatory T cells. Recently, at least six clinical studies targeting PDL1 or PD-1 on multiple myeloma have been started. In accordance with the current literature, we suggest that patients with myeloma can benefit anti PD-1/PDL1 therapy.